PT  - JOURNAL ARTICLE
AU  - R. A. Mclean
AU  - R. J. Geus
AU  - J. Pasternack
AU  - P. A. Mattis
AU  - G. E. Ullyot
TI  - PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR βTM 10
DP  - 1960 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 17--23
VI  - 129
IP  - 1
4099  - http://jpet.aspetjournals.org/content/129/1/17.short
4100  - http://jpet.aspetjournals.org/content/129/1/17.full
SO  - J Pharmacol Exp Ther1960 May 01; 129
AB  - Compound 6890, [2-(2,6-dimethylphenoxy) propyl]-trimethylammonium chloride monohy-drate or βTM 10 has been shown able to lower blood pressure and reduce heart rate in laboratory animals. These effects were seen in acute tests on anesthetized cats and dogs. They were also obtainable with long-term administration in unanesthetized animals. Pressor reflexes such as those following carotid artery occlusion or afferent vagal faradization were inhibited by 6890. A mode of action resembling that outlined for TM 10 by Exley (1957) was established for this analog. Its unique blocking effect seems to be selective for sympathetic nerve endings. Acute and 30-day toxicity tests did not reveal any histopathology or blood dyscrasia. Clinical trial of 6890 against hypertension and peripheral vascular disease in man should add to our understanding of the basic mechanisms responsible for these conditions.